Tags

Type your tag names separated by a space and hit enter

A study of community-acquired Mycoplasma pneumoniae in Yantai, China.
Colomb Med (Cali). 2018 Jun 30; 49(2):160-163.CM

Abstract

INTRODUCTION

Community-acquired pneumonia (CAP) is a global disease responsible for a large number of deaths, with significant economic impact. As diagnostic tools have increased in sensitivity, understanding of the etiology of CAP has begun to change. Mycoplasma pneumoniae is one of the major pathogens causing CAP. Macrolides and related antibiotics are first-line treatments for M. pneumoniae. Macrolide resistance has been spreading for 15 years and now occurs in worldwide. We undertook the first study on macrolide resistance of M. pneumoniae in Yantai. This may be helpful to determine the appropriate therapy for CAP in this population.

OBJECTIVE

To investigate the rate and mechanism of macrolide resistance in Yantai.

METHODS

Pharyngeal swab samples were collected from adult CAP patients. Samples were assayed by polymerase chain reaction (PCR) and cultivated to test for M. pneumoniae. Nested PCR was used to specifically amplify M. pneumoniae 23S rRNA gene fragments containing mutations, and amplicons were analyzed by CE-SSCP for macrolide resistance mutations. Results were confirmed by sequencing. Twenty-seven strains of M. pneumoniae were isolated and the activities of nine antibiotics against M. pneumoniae were tested in vitro.

RESULTS

Out of 128 samples tested, 27 were positive for M. pneumoniae. Mycoplasma 100% macrolides resistance to Mycoplasma pneumoniae. The mechanism of macrolides resistance was A2063G point mutation in the sequence directly binding to macrolides in the 23S rRNA V domain in vitro. The mean pyretolytic time for the fluoroquinolone group was 4.7 ±2.9 d, which was significantly shorter than 8.2 ±4.1 d for the azithromycin group.

CONCLUSIONS

Macrolides are not the first-line treatment for M. pneumoniae respiratory tract infections in Yantai.

Authors+Show Affiliations

Pneumology Department, Shandong Provincial Hospital. Shandong University, Jinan, China. Department of Infectious Diseases, Yantai Yuhuangding Hospital. Qingdao University, Yantai, China.Department of Infectious Diseases, Yantai Yuhuangding Hospital. Qingdao University, Yantai, China.Department of Infectious Diseases, Yantai Yuhuangding Hospital. Qingdao University, Yantai, China.Pneumology Department, Shandong Provincial Hospital. Shandong University, Jinan, China.Department of Infectious Diseases, Yantai Yuhuangding Hospital. Qingdao University, Yantai, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30104808

Citation

Yu, Hong-Xia, et al. "A Study of Community-acquired Mycoplasma Pneumoniae in Yantai, China." Colombia Medica (Cali, Colombia), vol. 49, no. 2, 2018, pp. 160-163.
Yu HX, Zhao MM, Pu ZH, et al. A study of community-acquired Mycoplasma pneumoniae in Yantai, China. Colomb Med (Cali). 2018;49(2):160-163.
Yu, H. X., Zhao, M. M., Pu, Z. H., Ju, Y. R., & Liu, Y. (2018). A study of community-acquired Mycoplasma pneumoniae in Yantai, China. Colombia Medica (Cali, Colombia), 49(2), 160-163. https://doi.org/10.25100/cm.v49i2.3813
Yu HX, et al. A Study of Community-acquired Mycoplasma Pneumoniae in Yantai, China. Colomb Med (Cali). 2018 Jun 30;49(2):160-163. PubMed PMID: 30104808.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A study of community-acquired Mycoplasma pneumoniae in Yantai, China. AU - Yu,Hong-Xia, AU - Zhao,Mao-Mao, AU - Pu,Zeng-Hui, AU - Ju,Yuan-Rong, AU - Liu,Yan, Y1 - 2018/06/30/ PY - 2018/8/15/entrez PY - 2018/8/15/pubmed PY - 2018/12/12/medline KW - Mycoplasma pneumoniae KW - adult KW - community-acquired pneumonia KW - drug resistance KW - therapy SP - 160 EP - 163 JF - Colombia medica (Cali, Colombia) JO - Colomb Med (Cali) VL - 49 IS - 2 N2 - INTRODUCTION: Community-acquired pneumonia (CAP) is a global disease responsible for a large number of deaths, with significant economic impact. As diagnostic tools have increased in sensitivity, understanding of the etiology of CAP has begun to change. Mycoplasma pneumoniae is one of the major pathogens causing CAP. Macrolides and related antibiotics are first-line treatments for M. pneumoniae. Macrolide resistance has been spreading for 15 years and now occurs in worldwide. We undertook the first study on macrolide resistance of M. pneumoniae in Yantai. This may be helpful to determine the appropriate therapy for CAP in this population. OBJECTIVE: To investigate the rate and mechanism of macrolide resistance in Yantai. METHODS: Pharyngeal swab samples were collected from adult CAP patients. Samples were assayed by polymerase chain reaction (PCR) and cultivated to test for M. pneumoniae. Nested PCR was used to specifically amplify M. pneumoniae 23S rRNA gene fragments containing mutations, and amplicons were analyzed by CE-SSCP for macrolide resistance mutations. Results were confirmed by sequencing. Twenty-seven strains of M. pneumoniae were isolated and the activities of nine antibiotics against M. pneumoniae were tested in vitro. RESULTS: Out of 128 samples tested, 27 were positive for M. pneumoniae. Mycoplasma 100% macrolides resistance to Mycoplasma pneumoniae. The mechanism of macrolides resistance was A2063G point mutation in the sequence directly binding to macrolides in the 23S rRNA V domain in vitro. The mean pyretolytic time for the fluoroquinolone group was 4.7 ±2.9 d, which was significantly shorter than 8.2 ±4.1 d for the azithromycin group. CONCLUSIONS: Macrolides are not the first-line treatment for M. pneumoniae respiratory tract infections in Yantai. SN - 1657-9534 UR - https://www.unboundmedicine.com/medline/citation/30104808/A_study_of_community_acquired_Mycoplasma_pneumoniae_in_Yantai_China_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/30104808/ DB - PRIME DP - Unbound Medicine ER -